Clinical trial NCT06435858: Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
Official title: Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Autosomal Dominant Polycystic Kidney Disease
Keywords: phosphate
calcium
magnesium
Empagliflozin
ADPKD
Lead sponsor: Cantonal Hospital Graubuenden
Sponsor class: OTHER
Collaborators: name: University of Zurich
First posted: 2024-05-30
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Investigator-initiated randomised, single-blind, placebo-controlled, cross-over study
Primary purpose: TREATMENT

Brief summary: This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.

Patients will be randomized into two groups and take Empagliflozin or a Placebo for 2 weeks with a wash-out period of 2 weeks. The primary outcome is tubular handling of the divalent ions calcium, phosphate and magnesium. Secondary outcomes include diuresis, safety and tolerability.

Detailed description: This investigator-initiated randomised, single-blind, placebo-controlled cross-over study aims to better understand tubular electrolyte handling of divalent ions in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.

After randomization, at week 0, participants collect 24-hour urine sample and a patient visit to assess vitals and blood tests takes place. After this visit, period 1 starts with a 2-week treatment of either Empagliflozin 10mg or Placebo.

At week 2, the second 24-hour-urine sample and 2. patient visit and blood test take place. After this visit, wash-out period for 2 weeks starts where no study drug will be administered At week 4, the period 2, the crossover-period starts for an additional 2 weeks. At week 6; a final and third 24-hour urine sample, clinical visit and blood test takes place.

At week 3 \&amp; 7, a phone consultation will assess safety.

Eligibility criteria: Inclusion Criteria:

* - Patients 18-75 years old with ADPKD, defined according to international diagnostic and classification criteria14, treated at Cantonal Hospital Graubünden (KSGR) and the University Hospital Zürich (USZ) independent of baseline treatment with the vasopressin receptor antagonist Tolvaptan
* Informed consent as documented by signature

Exclusion Criteria:

* - renal replacement therapy or kidney allograft recipient
* chronic kidney disease CKD KDIGO Stage G4 (eGFR under 30ml/min/1.73m2)
* patients younger 18 years of age
* Diabetes mellitus type 1
* recurrent urinary tract infections (UTI) defined as more than 3 infections requiring antibiotic treatment or over 1 requiring hospitalization/year.
* Patients with uncontrolled hypertension (defined as ambulatory systolic BP over 180mmHg), liver cirrhosis (Child Pugh B and C)
* Patients not able or not willing to stop the following medications during the study period of participation in the trial:
* Thiazide diuretics
* Carbonic anhydrase inhibitors
* Sodium bicarbonate
* 1, 25 (OH) vitamin D (calcitriol)
* Bisphosphonate, denosumab, teriparatide
* Pregnant or lactating women
* Known allergy to study drug
* Inability to understand and follow the protocol

Primary outcomes:
measure: Primary Outcome
timeFrame: After a two week intervention
Secondary outcomes:
measure: Secondary Outcome
timeFrame: After a two week intervention
Other outcomes:
Locations:
city: Chur
country: Switzerland
facility: Cantonal Hospital Graubuenden
state: Graubuenden
city: Zürich
country: Switzerland
facility: University Hospital Zurich, Division of Nephrology
state: Zurich
Study officials:
affiliation: Cantonal Hospital Graubuenden
name: Thomas Fehr, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cantonal Hospital Graubuenden
name: Patrick Hofmann, MD
role: PRINCIPAL_INVESTIGATOR
References: